BSI 706
Alternative Names: Anti-claudin-18.2 monoclonal antibody - Biosion; BSI-077; BSI-706Latest Information Update: 02 Dec 2021
At a glance
- Originator Biosion
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Gastric cancer
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Dec 2021 Biosion plans a phase I trial in Solid tumours in 2021/2022 (Biosion pipeline, December 2021)
- 29 Nov 2021 Biosion has patent for BSI 706 for discussion under Confidential Disclosure Agreement (CDA) (Biosion website, November 2021)
- 29 Nov 2021 Pharmacodynamics data from a preclinical study in Solid tumours released by Biosion